French device manufacturer, Eyevensys, has received approval from the French product security regulatory agency (ANSM) to advance its technology into clinical development.
The EyeCET platform uses the company’s electro-transfection injection system to deliver plasmids that encode for the production of disease-specific therapeutic proteins in the ciliary muscle of the eye.
The company’s lead product, EYS606, uses a plasmid encoding for the production of anti-TNFα for the treatment of non-infectious uveitis.
EYS606 has been granted an orphan drug designation by the EMA for the treatment of NIU. — Cynthia Jessup
